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Apolipoprotein D (Apo D) is a key molecule in the lipid transport during homeostasis
and repair processes in normal and pathological conditions of the nervous system with
a putative neuroprotective effect. In the last decades, huge experimental efforts have
been made to know the exact mechanism of action of Apo D, even though, it remains
an open question. In this regard, studies in mammals and flies have suggested that
Apo D seems to act through a variety of cellular mechanisms related with its ability
to selectively bind different lipid ligands. For instance, this apolipoprotein is required to
myelin compaction, it participates in axon regeneration/remyelination, and it can control
the magnitude and timing of the inflammatory response after injury, promoting myelin
clearance, and regulating the number of immune cells recruited to the damaged area.
These, among others, are some of the reasons to study Apo D in multiple sclerosis
(MS) pathology, where it could be particularly important since the autoimmune reaction
against oligodendrocytes (OLGs) and myelin is generally assumed as the most plausible
cause of this pathology. The aim of this work was to investigate the Apo D expression
pattern in MS lesions, including active and inactive demyelinating plaques, and also
remyelinating ones. Human brain tissues with inflammatory demyelination consistent
with MS were used to quantify Apo D immunosignal in different lesions. Our results
show a clear decrease of Apo D expression in all sclerosis plaques, being lower in
the inactive than in active areas but recovers in the remyelination ones. Apo D is
mainly produced by the matured OLGs of white matter and is located in cell processes
surrounding the myelin sheath. All these data seem to indicate an important role of Apo
D in myelination/remyelination processes as a molecule with a neuroprotective potential,
and may serve as a good starting point for its study in MS.
Keywords: demyelination, remyelination, myelin, axon loss, oligodendrocytes, neurodegenerative diseases
Abbreviations: AD, Alzheimer’s disease; Apo D, Apolipoprotein D; Apo E, Apolipoprotein E; BBB, blood–brain barrier;
BSA, bovine serum albumin; CNS, central nervous system; CSF, cerebrospinal fluid; DAB, diaminobenzidine; HDL, high-
density plasma lipoproteins; HRP, horseradish peroxidase; IL-1, interleukin 1; LFB, luxol fast blue; MS, multiple sclerosis;
OLGs, oligodendrocytes; OPCs, oligodendrocytes precursor cells; PAS, periodic acid–Schiff; PBS, phosphate-buffered saline;
PNS, peripheral nervous system; PPMS, primary progressive MS; RA, retinoic acid; SPMS, secondary progressive MS; WM,
white matter.
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INTRODUCTION
Multiple sclerosis (MS) is a chronic, neurodegenerative, and
demyelinating disease of the central nervous system (CNS) that
affects to more than 2.1 million people worldwide and for which
there is still no cure (Ramagopalan et al., 2010). The main
processes that characterize MS are demyelination and axonal
damage followed, in some cases, by remyelination events in
an attempt to restore the induced damage. The exact cause of
MS remains unknown, but an exacerbated autoimmune reaction
against oligodendrocytes (OLGs) and myelin protein, and the
resulting chronic inflammation have been postulated as the most
plausible origins (McQualter and Bernard, 2007; Zindler and
Zipp, 2010).
In MS, autoreactivity to different myelin proteins involves
cellular and humoral immunity. It has been described
that a defective and permeable blood-brain barrier (BBB)
can lead to some T lymphocytes to infiltrate the brain
parenchyma, secrete proinflammatory cytokines, and stimulate
monocytes/macrophages that promote damage of myelin sheaths
and the loss of OLGs (McQualter and Bernard, 2007; McGuire
et al., 2011). For its part, the humoral response implies the
activation of B lymphocytes with the secretion of anti-myelin
antibodies (Disanto et al., 2012). The main consequence of
the inflammation-mediated demyelination is an acute axonal
degeneration. Thus, limitation of electrical impulses can be
manifested as a decrease in conduction speed, a failure to
transmit the action potential at high frequencies, or as a total
conduction blockage leading to neurological dysfunction (Fuller
and Goodman, 2001).
MS focal demyelinating lesions, known as plaques, appear
as scars in the white matter (WM) throughout the brain and
spinal cord (Zindler and Zipp, 2010). Often, these pathological
features evolve differently during disease phases and, even,
plaques in different stages of demyelinating activity are evident
in the same phase. The active plaques characterized by the
presence of activated mononuclear cells, OLGs, and myelin
debris are common in the acute phase. For its part, chronic
inactive and completely demyelinated plaques appear as the MS
progresses; they show minor cellular infiltration and a substantial
loss of axons and OLGs (Popescu et al., 2013). Under specific
circumstances and in some sclerosis plaques, remyelination can
occur (shadow plaques). The entire myelin sheath is restored
in demyelinated axons, reinstating saltatory conduction, and
resolving functional deficits. This transient process is largely due
to the so-called OLGs precursor cells (OPCs) that are recruited to
the damaged areas (Frohman et al., 2006).
Apolipoprotein D (Apo D) belongs to the lipocalin family
whose members share the ability to bind and transport small
hydrophobic ligands, that is, arachidonic acid, cholesterol, or
steroids, due to their conserved tertiary structure with a ligand-
binding pocket (Rassart et al., 2000; Ruiz et al., 2013). This
29 kDa glycoprotein is ubiquitously expressed in neural and
peripheral tissues, detected in cerebrospinal fluid (CSF) and as
an important component of high-density plasma lipoproteins
(HDL) (Rassart et al., 2000). In the peripheral nervous system
(PNS), Schwann cells contribute to local synthesis of Apo D
and its expression is strongly induced after nerve injury (Spreyer
et al., 1990; Ganfornina et al., 2010; García-Mateo et al., 2014,
2018). Furthermore, axonal regeneration and remyelination
are delayed in Apo D knock out (KO) mice, which proves,
unequivocally, the apolipoprotein involvement in myelination
processes (Ganfornina et al., 2010).
In non-pathological conditions of the CNS, Apo D expression
is always greater in the WM than in the gray one and is widely
expressed in many nervous cells such as periventricular cells,
neurons, OLGs, and astrocytes (Navarro et al., 1998, 2010; Hu
et al., 2001). Noteworthy, Apo D is progressively accumulated
in neurons and astrocytes during aging, in several types of CNS
injury and neurodegenerative diseases as Parkinson, spongiform
encephalopathy, Niemann-Pick, or Alzheimer’s disease (AD)
(Muffat and Walker, 2010; Dassati et al., 2014). Evidence supports
a correlation between this Apo D up-regulation and lipid
transport during homeostasis and repair processes in normal
and pathological conditions. In this sense, it expression in the
cytoplasm and in OLGs processes of the WM seems to be
crucial for the myelin sheath formation during development
(Navarro et al., 2004). In recent decades, there is evidence of
the potential of Apo D as neuroprotective molecule, preventing
lipid peroxidation and excitotoxic injury (Ganfornina et al.,
2008; Bajo-Grañeras et al., 2011), and contributing to neuronal
trophism (Kosacka et al., 2009). Interestingly, those neurons most
vulnerable to death are unable to synthesize or capture Apo D
(Ordoñez et al., 2006).
Data from proteomic studies have currently suggested that
various apolipoproteins, Apo D and Apo E among them, are
involved in MS; elevated levels of these proteins were found
in the CSF of MS patients (Stoop et al., 2010). Unfortunately,
there are few studies on evaluating the implication of Apo D
in the pathology, and in some cases, the results are seemingly
contradictory (Reindl et al., 2001; Kroksveen et al., 2012). The aim
of the present study was to analyze, for first time to or knowledge,
the Apo D expression pattern in focal areas of myelin loss and
its relationship with demyelination and remyelination processes
in MS, in an attempt to know the exact role of Apo D in the
pathology.
MATERIALS AND METHODS
Subjects
The present study was conducted according to the Declaration of
Helsinki, and it has been approved by the local Research Ethics
Committee of Principado de Asturias.
Human brain and spinal cord tissues were provided by several
Spanish brain banks: Biobank of the University Central Hospital
of Asturias (n = 3), Barcelona University-Clinical Hospital
(n = 6), Central Bank Madrid (CIEN Foundation) (n = 1), and
Navarra Hospital (n = 4). Eleven subjects between 27 and 68 years
old with histologically proven inflammatory demyelination
consistent with MS, properly confirmed by a neuropathologist,
were used in this study (Table 1). The ethics committees of
each participating biobank have reviewed and approved the study
protocol. Whereas most biobanks waived the need for informed
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consent due to the anonymous and non-interventional fashion
of this study, a formal written consent obtained from patients or
surrogates was an essential requirement for other ones.
Human brain and spinal cord samples were fixed by
immersion in 10% buffered formalin. After fixation, pieces
were dehydrated, cleared in butyl acetate, and embedded in
paraffin. Sections about 5–7 µm thick were obtained, mounted
on “SuperFrost Plus” (Mentzel-Glasse) slides, and dried at 36◦C
for 24 h.
Cytoarchitectonic Staining
To visualize the morphological features and the different cell
types in the studied regions, sections were desparaffined in
xylene, and partially hydrated by successive alcohols. Then, and
in order to locate demyelination plaques and determine lesion
activity, sections were stained using hematoxylin-eosin, luxol
fast blue (LFB) myelin stain, periodic acid–Schiff (PAS), and
ferric hematoxylin, a technique developed in our laboratory
(Tolivia et al., 1988), which specifically stains myelin without
differentiation process. This technique is a simple method for
the differential staining of myelinated nerve fibers (blue/black
color) and cell bodies (red color) in two steps; first step with
ferric hematoxylin and second with pyronine (Tolivia et al.,
1988). According demyelinating activity (Lucchinetti et al., 1999;
Bramow et al., 2010; Popescu et al., 2013), the following stages
were defined: active areas located at the plaque border between
demyelinated plaque and periplaque WM, inactive areas that
showed a complete demyelination and, finally, remyelinating
areas characterized by clusters of axons surrounded by myelin
sheaths within demyelinated plaques. The staging in each
lesion was performed independently by two of the authors
(AN and BR).
Immunohistochemistry
Apo D Detection
For immunohistochemistry, sections were treated with Triton
X (0.1%, 5 min), washed in distilled water, treated with H2O2
(3%, 5 min), washed in distilled water, and treated with PBS
(2 min). Non-specific binding was blocked by incubation with
1% BSA (30 min). Incubation with a specific rabbit antibody
against human Apo D [1:2000 dilution, provided by Dr. Carlos
López-Otín, Universidad de Oviedo (López-Boado et al., 1994;
Navarro et al., 1998, 2004; Ordoñez et al., 2006)], was carried
out overnight at 4◦C. After several washes in PBS, sections
were incubated at room temperature using a biotinylated horse
universal antibody (Vector, PK-8800) (1:40 dilution, 30 min).
Afterward, sections were treated with extravidin labeled with
HRP (Sigma Extra-3, Sigma Chemical Co). The peroxidase
activity was visualized with 0.05% diaminobenzidine (DAB)
(D5637, Sigma Chemical Co) in 50 mM Tris buffer pH 7.6,
containing 0.04% H2O2 (33%). Sections were counterstained
with a modification of formaldehyde thionin method (Reynolds
et al., 1994; Tolivia et al., 1994; Vazgiouraki et al., 2016),
dehydrated, cleared in eucalyptol, and mounted with Eukitt.
For controls, representative sections were processed in the
same way with 1% BSA in place of the primary antibody.
In addition, control sections were also incubated with Apo
D antibody preabsorbed with Apo D immunizing peptide
(80 µg/ml). Under these conditions, no specific immunostaining
was observed.
Before quantification, we took advantage of the fluorescent
qualities that myelin displays in formalin fixation to choose
different areas in demyelination plaques: active, inactive, and
remyelinization areas. For the quantification of Apo D presence,
the chromogenic signal was selected with Adobe Photoshop CS
8.0.1 (Adobe Systems Inc., CA, United States) and quantified
with ImageJ 1.37c (National Institutes of Health, Bethesda, MD,
United States) software according to a procedure developed by
our group (Tolivia et al., 2006). Six random regions per case
(Table 1) were photographed using a 20× lens.
Double Immunostaining for Apo D and NF-200
A double immunostaining for Apo D protein and neurofilament
(NF-200) was carried out according to the following protocol.
The sections were treated sequentially with Triton X-100 (0.1%,
5 min), washed in distilled water, treated with H2O2 (3%,
5 min), washed in distilled water again, and treated with PBS
for 2 min. Non-specific binding was blocked by incubation with
1% BSA (30 min). Incubation with a specific rabbit antibody
against Apo D (1:2000 dilution) was carried out overnight at
4◦C. The immunoreactivity was detected with an Extravidin–
biotin–alkaline phosphatase staining kit (Sigma Extra-1A, Sigma
Chemical Co). Enzymatic activity was shown by incubation
with Vector blue substrate (Vector SK-5300; Burlingame, CA,
United States). Slides were rinsed in PBS, placed in a plastic
Coplin jar filled with 0.01 M sodium citrate buffer (pH 6),
and incubated in a household microwave oven. Microwave
treatment involves completely blocking contaminating staining
in the double-labeling technique using primary antibodies from
the same species and the same secondary antibody [see Lan et al.
(1995)]. Then, incubation with a specific monoclonal antibody
against NF-200 (Novocastra, NCL-NF200, 1:100 dilution) was
carried out overnight at 4◦C. The immunoreactivity was detected
using the Extravidin–biotin–peroxidase Staining kit (Sigma
Extra-3, Sigma Chemical Co). After several washes, peroxidase
was visualized with 0.05% DAB (D5637, Sigma Chemical Co)
in 50 mM Tris buffer (pH 7.6), containing 0.04% H2O2 (33%).
Finally, sections were mounted in aqueous mounting medium.
For controls, representative sections were processed in the
same way with 1% BSA in place of the primary antibody.
In addition, control sections were also incubated with Apo
D antibody preabsorbed with Apo D immunizing peptide
(80 µg/ml). Under these conditions, no specific immunostaining
was observed.
Double Immunostaining for Crystallin and Apo D
The double immunostaining for crystallin and Apo D protein
was carried out according to the following protocol. The sections
were treated sequentially with Triton X-100 (0.1%, 5 min),
washed in distilled water, treated with H2O2 (3%, 5 min),
washed in distilled water again, and treated with PBS for
2 min. Slides were rinsed in PBS, placed in a plastic Coplin jar
filled with 0.01 M sodium citrate buffer (pH 6), and incubated
in a household microwave oven. Then sections were washed
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in PBS for 2 min and non-specific binding was blocked by
incubation with 1% BSA (30 min). Incubation with a specific
monoclonal antibody against alpha B crystallin (Novocastra,
NCL-ABCrys-512) (1:200 dilution) was carried out overnight
at 4◦C. Sections were incubated with a biotinylated horse
universal antibody (Vector, PK-8800) (1:50 dilution, 30 min).
Afterward, sections were incubated with extravidin (Sigma Extra-
3, Sigma Chemical Co), and peroxidase activity was visualized
by incubation with Sigma Fast DAB (Sigma D4 168, Sigma
Chemical Co) at room temperature for 30 min. After that,
slides were rinsed in PBS, placed into a plastic coplin jar filled
with 0.01 M sodium citrate buffer (pH 6), and heated twice
for 5 min at 700 W in a household microwave. Microwave
treatment involves completely blocking contaminating staining
in the double-labeling technique using primary antibodies from
the same species and the same secondary antibody [see Lan
et al. (1995)]. Immunostaining for Apo D was carried out as
previously described and, after several washes in PBS, sections
were incubated for 30 min at room temperature in biotinylated
horse universal antibody (Vector, PK-8800) diluted 1:50. Sections
were subsequently incubated with streptavidin labeled with
Fluorolink Cy3 (Amersham, PA-43001). The sections were
not counterstained and were mounted in aqueous mounting
medium. For controls, representative sections were processed in
the same way with 1% BSA in place of the primary antibody.
In addition, control sections were also incubated with Apo
D antibody preabsorbed with Apo D immunizing peptide
(80 µg/ml). Under these conditions, no specific immunostaining
was observed.
Final images were obtained by the digital superposition of the
corresponding DAB (crystallin signal) and fluorescence (Apo D
signal) images of the same sections. The positive signal of each
image was selected according to the method of Tolivia et al.
(2006); crystallin DAB signal was converted to green and Apo
D signal to red channel of a new RGB picture. This new image
shows the Apo D fluorescence signal in red and the crystallin
fluorescence signal in green.
Finally, a double immunohistochemical technique for
crystallin and the specific astrocytic marker, GFAP, was
performed in order to study the possible crystallin expression
in other CNS cells. The immunohistochemistry was carried out
according to the method described above; a specific monoclonal
antibody against alpha B crystallin visualized by Sigma Fast DAB
and a specific polyclonal antibody against GFAP (Sigma; G-9269;
1:500 dilution, Sigma Chemical Co) visualized by streptavidin
labeled with Fluorolink Cy2 (Amersham, PA-42001) were used.
Final images were obtained by the digital superposition of the
corresponding DAB (crystallin signal) and fluorescence (GFAP
signal) images of the same sections. Crystallin DAB signal was
converted to red and GFAP signal to green channel of a new RGB
picture. This new image shows the GFAP fluorescence signal in
green and the crystallin fluorescence signal in red.
Microscopy Observation
Sections were observed using an Epi-Fl Nikon Eclipse E400
microscope equipped with Plan-Fluor objectives, and images
were recorded by a digital camera (NikonDN-100).
Statistical Analysis
The data in the graphs are presented as the mean ± SEM.
All statistical calculations were conducted using SPSS 21.0 for
Windows. The test of Kolmogorov–Smirnov with the correction
of Lilliefors was used to evaluate the fit of the data to a normal
distribution and the test of Levene to evaluate the homogeneity
of variance. Significance was analyzed by one-way ANOVA test
followed by a Tukey’s test for multiple comparisons, or a Student’s
t-test. Significant differences were considered when p< 0.05.
RESULTS
Identification and Characterization of
Focal Demyelinating Plaques
In order to analyze the Apo D expression in MS lesions, first
of all we localized and characterized demyelination plaques
in myelin stained sections according with previous studies
(Lucchinetti et al., 1999; Bramow et al., 2010; Popescu et al.,
2013). Different plaque types and stages of demyelinating activity
were found. Acute active plaques were observed as partially
demyelinated lesions with abundant and widely distributed
macrophages containing myelin debris, and reactive astrocytes.
Also many lymphocytes, as well as, other immune cells appeared
in these lesions (Figures 1a,b). Chronic-active plaques were more
frequently detected than acute active ones probably due to the
high number of patients with progressive MS. Chronic-active
plaques consist in big plaques with an inactive center and one or
more expansive edges with macrophages inside (Figures 1c,d).
In some cases, chronic-active plaques with remyelination can be
observed (Figure 1e).
The staining for myelin not only allowed us to delimit
the chronic-active plaques but also to distinguish different
morphological areas within lesions: (Ramagopalan et al., 2010)
periplaque WM area, the surrounding WM that seems not to
be affected by demyelination (McQualter and Bernard, 2007)
plaque active area, containing myelin-laden macrophages and
partially demyelinated (Zindler and Zipp, 2010), and plaque
inactive center with a drastic reduction or even absence of
myelin (Figure 1c). Since 27% of our cases showed remyelination
features, a new region called remyelinating area (McGuire et al.,
2011) was incorporated to the study. This area is characterized by
the existence of small packages of newly formed myelinated nerve
fibers crossing the demyelinated region.
Apo D Expression Pattern in MS Plaques
In order to analyze the Apo D implication in demyelination
and remyelination processes in MS, we analyzed the Apo
D expression pattern in focal demyelinating lesions by
immunohistochemistry techniques (Figures 2a–d).
The active plaque areas show a low overall Apo D signal when
we compare with the intact periplaque WM. However, reactive
astrocytes and active macrophages of these areas appear intensely
labeled for Apo D (Figures 2e,f); most astrocytes positives for
this protein exhibit round-shaped cell bodies, hypertrophy, and
numerous fibrillary processes (reactive astrocytes).
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FIGURE 1 | Representative images of histochemical characterization of lesions with ferric hematoxylin. Acute active plaque arround a vessel where no completely
loss of myelin was found in a male patient of 58 years old (a). Extravasated mononucleated cells in acute active plaque of the same patient. Scale bar: 10 µm (100×)
(b). Chronic active plaque with three characteristic areas in a female patient of 48 years old: periplaque WM, border area, and inactive center plaque. Scale bar
50 µm (4×) (c). Macrophages around vessels in chronic active plaque edge (arrows). Scale bar: 50 µm (20×) (d). Chronic active plaque with remyelination in a male
patient of 58 years old, shadow plaques are also observed (arrowheads). Scale bar 50 µm (4×) (e).
In the case of chronic plaques, Apo D expression was again
higher in periplaque WM than in the inactive plaque area
(Figures 2g,h). This fact may be due to the large amount of Apo
D-positive cells present in these surrounding areas as well as the
intensity of their labeling (Figure 2g).
When we analyze myelin of chronic MS lesions with a specific
stain for this protein we found that, as it was to be expected,
myelin was reduced to low levels in active areas and to very
low levels in inactive ones, compared to control WM area and
periplaque WM (Figures 3a,d,g,j). Interestingly, the Apo D
immunosignal showed a similar pattern than that of myelin.
Thus, the immunoreactivity for Apo D tended to decrease as we
approached the plaque border and even more in the demyelinated
plaque area (Figures 3b,e,h,k). Based in the cell morphology,
we observed that OLGs, macrophagic cells, and some isolated
astrocytes (inserts in Figures 3e,h) were responsible for the
expression of Apo D in all these areas (Figures 3b,e,h,k,n). In
the remyelinating regions, both myelin and Apo D levels increase
in line with the remyelination processes that are taking place
(Figures 3m,n).
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FIGURE 2 | Representative images of histochemical and immunohistochemical comparison of different lesion areas in a chronic active plaque. Focal active
demyelinated lesion in periventricular WM (a,b). Consecutive sections of a male patient, 35 years old. (a) Myelin stain with ferric hematoxylin. (b)
Immunohistochemistry for Apo D. Expanding rim of a chronic active plaque surrounding an inactive area (c,d). Consecutive sections of a male patient, 68 years old.
(c) Myelin stain ferric hematoxylin. (d) Immunohistochemistry for Apo D. Scale bar 50 µm (4×). Immunopositive cell types in plaques. Reactive astrocytes with large
cytoplasm, round nuclei, and stellate neurites (e). Macrophagic cell with numerous phagosomes inside (f). Many small OLGs with small round nuclei, scarce
cytoplasm, and one or two projections (g). Negative immunostaining in inactive plaque (h). Scale bar 10 µm (100×).
Finally, co-localization studies of myelin and Apo D proteins
were performed in immunohistochemistry tissue sections
counterstained with LFB (Figures 3c,f,i,l,o). We found that
Apo D appeared preferentially in the cytoplasm and distal cell
processes of OLGs in all the plaque types and patients studied.
Small granules containing Apo D could also be observed around
the myelin sheath of these cells (Figures 3c,f,i,o). Noteworthy,
in the border of plaques, even with low levels of myelin, some
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FIGURE 3 | Representative images of histochemical and immunohistochemical comparison of different lesion areas in a chronic active plaque. Control WM of male
control subject of 66 years old. (a) Characteristic myelin pattern in WM area. (b) Consecutive section immunostained for Apo D. (c) Colocalization of myelin and Apo
D immunohistochemistry in cytoplasm and processes of OLGs. Female subject of 52 years old with MS (d–o). Periplaque WM. (d) Characteristic myelin pattern in
periplaque area. (e) Consecutive section immunostained for Apo D showing mainly positive OLGs (arrow), but also astrocytes (arrowhead) as it is shown in the insert.
(f) Colocalization of myelin and Apo D immunohistochemistry in cytoplasm and processes of OLGs. Apo D containing granules were found surrounding myelin
sheath. Active area. (g) Active demyelination can be observed in this area. (h) Intensity of the immunostaining for Apo D is weaker than in the periplaque WM. Apo D
positive macrophagic cells (top insert) and less OLGs can be observed in this area (bottom insert). (i) Double stain for myelin and Apo D. The arrowhead points to the
granular content of distal processes of OLGs around myelin sheath. Inactive area. (j) Myelin stain shows a completely demyelinated area. (k) This area is negative for
Apo D with the exception of a few astrocytes with a weak staining (insert). (l) No myelin nor Apo D label can be found in inactive plaque area. Remyelination area in a
sclerosis plaque. (m) A package of myelinated axons passing by a demyelinated area. (n) Consecutive section immunostained for Apo D. Positive OLGs can be
observed in this area (arrow in the insert). (o) Myelinated axons stained with LFB also present granular Apo D immunostaining surrounding (arrowheads). Scale bars:
(a,b,d,e,g,h,j,k,m,n), 30 µm (10×); (c,f,i,l,o), 10 µm; (Inserts), 10 µm (100×).
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remaining OLGs showed immunolabeling for Apo D (Figure 3i).
OLGs expressing Apo D reappeared in focal remyelination areas,
specifically in those where new myelin envelopes are being
formed (Figure 3o).
Quantification of Apo D Levels in Chronic
MS Plaques
The quantification of Apo D protein level in the most frequent
and better defined chronic plaques showed clear discrepancies
between the different areas under study. Since it was difficult
to distinguish plaque areas in immunostaining sections for
Apo D, we used the intrinsic fluorescent properties of myelin
to unequivocally detect them and improve the quantification
process (Figures 4a–f). The data showed statistically significant
differences in the Apo D burden between inactive (36.5 ± 8.2)
and active areas (76.6 ± 14.3) in chronic plaques (p < 0.05),
and also between inactive and remyelination areas where Apo D
recovers (71.25± 18.7; p< 0.05), taking periplaque WM as 100%
expression (Figure 4g). However, we did not find significant
differences when we compared active with remyelination areas
(Figure 4g).
Apo D and Crystallin Co-localization
Our results clearly demonstrated a decrease in the Apo D content
from the active area to the chronic inactive one in parallel with
the loss of myelin in all the plaque types and patients studied.
However, an important issue still to be determined is the exact
relationship between Apo D levels and the number of OLGs
present in these areas. For this purpose, first we tested different
OLG markers and we found that crystallin (Pountney et al., 2005;
Patel and Balabanov, 2012; Mallucci et al., 2015) was the best
since it was able to unequivocally detect OLGs in tissues without
myelin interactions, corroborating our glial cell identification
based on their specific morphological characteristics (data not
shown). Second and in order to confirm that crystallin is
expressed specifically in OLGs, a double immunohistochemical
technique for crystallin and the specific astrocytic marker
GFAP was performed. Our results clearly demonstrated no
colocalization between these two markers and, consequently, that
crystallin immunoreactive cells are in virtually all case OLGs
(Supplementary Figure S1). In fact, only a very few astrocytes
were positives for crystallin so these cells have not been taken into
account in our studies.
Double immunostaining for Apo D and crystallin is showed
in Figure 5, in both representative images (Figures 5a–d),
and the quantification of OLGs negative for Apo D (only
positive for crystallin) and positive for Apo D (colocalization
between crystallin and Apo D signals) (Figure 5e). A statistical
significant reduction in the number of OLGs expressing Apo
D (colocalization signal) in the active area (13.04 ± 0.43)
compared with the periplaque WM (27.8 ± 0.45; p < 0.001),
and a significant number of OLGs do not express Apo D in the
periplaque WM (31± 0.50 vs. 58.75± 0.94; p< 0.001) as well as
in active areas (17.1 ± 0.6 vs. 30.1 ± 1; p < 0.001) was found. In
fact, we have found that not all the OLGs are Apo D positives,
which becomes more evident in active demyelinating areas in
which there also seems to be more colocalization (Figures 5a–d).
Apo D Expression and Axonal
Preservation
In the light of the described results and the neuroprotective role
suggested for Apo D, we used a double immunostaining for Apo
D and NF-200 to study whether the apolipoprotein expression
could be related with axonal preservation. As we expected, the
expression pattern for both proteins was similar. In fact, the
immunolabeling for Apo D and NF-200 statistically significant
decreases in the chronic inactive plaque areas (12.18 ± 0.3 and
2.9± 0.07, respectively) compared to periplaque WM (29.5± 0.4
and 17.4± 0.23, respectively; p< 0.001) (Figures 6c–f). Notably,
we have observed that the amount of Apo D and neuronal
NF-200 decreased, in a statistical significant way, in parallel
from the edge (19.55 ± 0.7 and 6.4 ± 0.22, respectively) to the
inactive plaque center (12.18 ± 0.3 and 2.9 ± 0.07, respectively;
p < 0.001) (Figures 6a–c,e,f). Of note is that many axons
conserved immunostaining of NF-200 in active demyelination
areas even in absence of Apo D expression (Figure 6B). In
remyelination areas, both signals were again found (16.58 ± 0.5
and 14.32± 0.40, respectively) (Figures 6d–f).
DISCUSSION
While much progress has been achieved on the involvement
of Apo D in some neurodegenerative diseases in the
past years, little is known about its role in MS. The
neuroprotective and antioxidant effects postulated for this
apolipoprotein and its proved overexpression in glial cells
during demyelinating/remyelinating processes are fundamental
reasons to suspect that Apo D could be implicated in MS. The
immunohistochemical characterization of Apo D expression
pattern in the anatomopathological classical features of MS,
sclerosis plaques, is a first step necessary to address this goal.
In this work, we have observed that Apo D expression is
further reduced in MS lesions respect to the unaffected WM,
in all the plaque types and patients studied. In this sense, an
interesting finding is that there are labeling differences within
the plaque, significantly lower Apo D expression in the inactive
area than in the active one which increases again in remyelination
areas. Remarkably, the immunohistochemical approaches reveal
a possible relationship between OLGs, myelin, and Apo D
expression in MS plaques. As it was expected, myelin protein
levels decrease in demyelination plaques from the periplaque
WM to the border of the lesions an even more to the center.
In fact, this loss of myelin sheets wrapping myelinated nerve
fibers is closely related with OLGs degeneration that characterize
MS pathophysiology (Zindler and Zipp, 2010; Popescu et al.,
2013). The Apo D expression pattern in both active and chronic
plaques was similar than the one found for myelin. Apart
from myelination, mature OLGs as wells as OPCs are the cells
primarily responsible for the Apo D synthesis in the normal
WM of adult human brain, during CNS embryogenesis and in
myelin sheaths formation (Hu et al., 2001; Navarro et al., 2004).
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FIGURE 4 | Representative image of remyelination area in a sclerosis plaque. Immunohistochemistry for Apo D visualized under light microscopy (a,c,e), and same
area observed with fluorescent microscopy to visualize autofluorescence of myelin sheaths (b,d,f). Scale bar: 50 µm (10×). Histogram showing densitometric
quantification of Apo D (g). Bars represent mean density in 20× field ± SEM. ∗Statistically significant differences, p < 0.05. Periplaque WM was taken as 100% of
Apo D and the rest of the values relativized to it.
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FIGURE 5 | Double immunohistochemical technique for crystallin (DAB signal, brown) and Apo D (Cy3 fluorescence signal, red). (a,b) The bright-field micrographs of
crystallin signal (c,d) The digital superposition, on those section, of fluorescence signal for Apo D. Digital superposition shows clearly the absence of Apo D
expression in some OLGs (green signal) and OLGs with Apo D expression (yellow signal). Representative image of active plaque area (a,c). Representative image of
periplaque WM area (b,d). Scale bar: 20 µm. Histogram showing number of OLGs positive for crystallin (gray bars) and also labeled for Apo D (black bars;
colocalization signal) (e). Bars represent OLGs number in 20× field ± SEM. ∗∗∗Statistically significant differences active area versus periplaque WM, p < 0.001.
###Statistically significant differences Apo D versus crystallin, p < 0.001.
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FIGURE 6 | Double immunohistochemical technique for Apo D (blue) and NF-200 (brown). The representative micrographs show a chronic plaque where it can be
clearly distinguish the surveyed areas: periplaque WM area (a), active area (b), inactive area (c), and remyelination area (d). Scale bar: 60 µm. Histogram showing
densitometric quantification of Apo D (e). Histogram showing densitometric quantification of NF-200 (f). Bars represent mean density in 20× field ± SEM.
∗∗∗Statistically significant differences versus periplaque WM, p < 0.001. ###Statistically significant differences inactive center versus active area, p < 0.001. AU:
arbitrary units.
Bearing in mind these data, one could think that the Apo D
downregulation observed in sclerosis plaques is consistent with
OLGs death caused by an exacerbated autoimmune reaction.
However, we have demonstrated that not all OLGs express Apo
D in periplaque intact regions, which becomes more evident in
demyelinating areas. The OLG degeneration only could explain,
in our opinion, one part of the reduced Apo D levels, what
pathological processes of MS compromise, directly or indirectly,
Frontiers in Aging Neuroscience | www.frontiersin.org 12 August 2018 | Volume 10 | Article 254
fnagi-10-00254 August 18, 2018 Time: 18:55 # 13
Navarro et al. Apo D in Multiple Sclerosis
the expression of Apo D by the intact OLGs could explain the rest
(Patel and Balabanov, 2012).
Regarding the role of Apo D in myelination/remyelination
processes, literature indicates that Apo D is a secreted
lipocalin that takes place in a neuroprotective mode in various
pathophysiological mechanisms of CNS and PNS, almost always
in relation with its ability to selectively bind different small lipid
molecules (Rickhag et al., 2008; Kosacka et al., 2009; García-
Mateo et al., 2014). In this sense, Apo D is significantly up-
regulated in Schwann cells and macrophages of sciatic nerve after
crush injury (Boyles et al., 1990; Spreyer et al., 1990) where it
may promote recovery locomotor function after damage, myelin
clearance, and regulate the number of macrophages recruited
to the injury site, which means controlling the magnitude
and timing of the inflammatory response (Ganfornina et al.,
2010; García-Mateo et al., 2014). In fact, the lack of Apo D
seems to compromise myelin compaction but more importantly
myelin clearance after injury, resulting in a delayed axonal
regeneration/remyelination (Ganfornina et al., 2010; García-
Mateo et al., 2018). In addition, Apo D gene is among the
regeneration-associated genes whose expression is up-regulated
in rat dorsal root ganglia following chronic constriction injury of
the sciatic nerve (Kim et al., 2001). Despite the function of Apo D
in myelin homeostasis in the PNS is well known, its exact position
during myelination/demyelination processes of the CNS remains
unclear.
Apo D is expressed in the development of the CNS and
increases during aging and in some neurodegenerative diseases
(Navarro et al., 2004; Muffat and Walker, 2010; Sanchez et al.,
2015). Gene profiling analysis of ischemic and stroke rat brain
tissues showed the up-regulation of genes related to lipid
transport, including Apo D, mainly in peri-infarct and WM
areas in cells identified as mature OLGs and reactive astrocytes
(Rickhag et al., 2008). It has been proposed that Apo D may
exert a neuroprotective influence in the acute stroke phase and
may also support neuronal regeneration and remyelination in
the extended post-stroke recovery phase (Rickhag et al., 2008).
Demyelination, neuronal growth, and remyelination are among
the multiple events that take place in MS brains and that
require a synthesis and recruitment of lipids to form plasma
membranes and myelin sheaths. Noteworthy, we have found
that the expression of Apo D, one of the most important
glial-derived proteins in the myelin dynamics, decreases in
the sclerosis plaques of MS brains. On one hand, we have
observed Apo D label in cytoplasm and distal processes of
OLGs but no colocalization with myelin itself. On the other
hand, the decrease in Apo D protein is not only due to the
lower number of OLGs inside the plaques but many of these
OLGs are not able to express it. Activation of the inflammatory
cascade in MS ultimately compromise, directly or indirectly,
OLGs function and viability (Patel and Balabanov, 2012). In
this sense, it has been shown that inflammatory mediators such
as cytokines, that is, IL-1, released from microglia/macrophages
and astrocytes could alter Apo D expression in mature OLGs
(Rassart et al., 2000; Clausen et al., 2005). Probably this
exacerbated environment in the early stages of MS leads to
defects in modulating the Apo D expression in astrocytes
and OLGs which, together with the death of these latter,
may affect the demyelination/remyelination balance turning
it less effective, and contributing to the development of the
disease.
Also of interest is highlighting that Apo D disappears in
demyelinated plaques but returns when remyelination occurs.
According with our findings, a correlation between Apo D and
loss of axonal processes in the sclerosis plaques could be ruled
out. Although more studies are needed in this respect, one
plausible explanation may place Apo D in the molecular and
cellular mechanism that control spontaneous remyelination after
damage. As mentioned above, Apo D is expressed mainly by
mature OLGs as wells as OPCs in the brain which, in turn,
are ultimately responsible for the restoration of new myelin
sheaths in demyelinated axons in MS (Hu et al., 2001; Bradl
and Lassmann, 2010; Clemente et al., 2013; de Castro et al.,
2013). Indeed, it seems that adult OPCs react to damage and
are able to proliferate, migrate, and differentiate in response
to mitogens and pro-migratory factors secreted by astrocytes
and microglial cells to replace lost OLGs (Clemente et al.,
2013). Some of the neuroprotective functions of Apo D in
this context could be related with recent findings that suggest
that it may regulate the migratory behavior of different motile
cells in association to growth factors (Dentelli et al., 1999;
Leung et al., 2004; Pajaniappan et al., 2011; Elo et al., 2012).
A possible link between Apo D expression/recapture and OPCs
differentiation is another factor to take into account. The Apo
D implication in cell differentiation has been assessed previously
in both in vivo and in vitro studies (López-Boado et al., 1994;
Kosacka et al., 2009). The data showed that Apo D may act
as neurotrophic factor that promotes neurite outgrowth and
synaptogenesis in dorsal root ganglion neurons (Kosacka et al.,
2009). Interestingly, it has been also shown that Apo D seems
to mediate neuronal differentiation in a retinoic acid (RA)-
dependent manner in various cell lines; Apo D may act as
RA carrier (Ruiz et al., 2013). Unfortunately, remyelination
finally fails in this pathology most likely due to the shortage of
OLGs and/or by an inadequate supportive environment for their
differentiation.
Apart from OLGs and macrophages, astrocytes also express
Apo D in WM. Our group and others have previously reported
that in some human neurodegenerative diseases, reactive glial
progression seems to be accompanied by an increase in Apo
D expression being this increment much higher in astrogliosis
areas, probably due to neuron injury or loss (Ordoñez et al., 2006;
Bajo-Grañeras et al., 2011; Dassati et al., 2014). Accordingly, we
have observed that some reactive astrocytes in active plaques
show an intense immunosignal for Apo D but, surprisingly,
astrocytes in the edge of plaques or even within the glial scar
in the chronic plaques show a much lower signal. Since one of
the postulated role for Apo D is to act as a neuroprotective and
antioxidant molecule, one could expect that Apo D expression
would be higher in periplaque and active areas of MS plaques.
This apparent contradiction could be explained again by the
influence of MS local levels of cytokines in the astrocyte
protein expression profiles (Rassart et al., 2000; Holley et al.,
2003).
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CONCLUSION
In summary, the dual function of Apo D, as a tissue specific
lipid carrier and an antioxidant and neuroprotective molecule,
makes it a potential versatile player in MS pathology. To
our knowledge, this is the first study showing a detailed
characterization of Apo D expression pattern not only in the MS
lesions but also in different types of cells somehow involved in
the disease. Our results seem to indicate an important function
of Apo D in MS and may serve as a good starting point for
its study in the myelination/remyelination of CNS. However,
further investigation is needed to appropriately address the
exact implication of Apo D in these processes as well as its
neuroprotective potential that, if confirmed, would open new
avenues in the search for alternative therapeutically approaches
in the fight against demyelinating diseases as MS.
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